Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action

@article{Yu2017SelectiveAR,
  title={Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action},
  author={Ziyang Yu and S. He and Dannie Wang and H. Patel and C. P. Miller and J. Brown and G. Hattersley and J. Saeh},
  journal={Clinical Cancer Research},
  year={2017},
  volume={23},
  pages={7608 - 7620}
}
  • Ziyang Yu, S. He, +5 authors J. Saeh
  • Published 2017
  • Medicine
  • Clinical Cancer Research
    • Purpose: Steroidal androgens suppress androgen receptor and estrogen receptor positive (AR/ER+) breast cancer cells and were used to treat breast cancer, eliciting favorable response. The current study evaluates the activity and efficacy of the oral selective AR modulator RAD140 in in vivo and in vitro models of AR/ER+ breast cancer. Experimental Design: A series of in vitro assays were used to determine the affinity of RAD140 to 4 nuclear receptors and evaluate its tissue-selective AR activity… CONTINUE READING
    View on AACR
    clincancerres.aacrjournals.org
    9 Citations
    Background Citations
    2
    Results Citations
    1
    9 Citations
    Citation Type

    Citation Type

    The cellular and molecular effects of the androgen receptor agonist , Cl-4 AS-1 , on breast cancer cells
    • PDF
    The cellular and molecular effects of the androgen receptor agonist, Cl-4AS-1, on breast cancer cells
    • 1
    Nuclear receptors: recent drug discovery for cancer therapies.
    • 19
    • PDF
    The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome
    • 23
    • PDF
    Comparison of the three SARMs RAD-140, GLPG0492 and GSK-2881078 in two different in vitro bioassays, and in an in silico androgen receptor binding assay
    • 5
    Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition.
    • 15
    Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials
    • 3
    Metabolic studies of selective androgen receptor modulators RAD140 and S-23 in horses.
    Considerations, possible contraindications, and potential mechanisms for deleterious effect in recreational and athletic use of selective androgen receptor modulators (SARMs) in lieu of anabolic androgenic steroids: A narrative review

    References

    SHOWING 1-10 OF 74 REFERENCES
    Targeting androgen receptor in estrogen receptor-negative breast cancer.
    • 283
    • PDF
    Targeting the Androgen Receptor in Breast Cancer
    • 73
    • PDF
    Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line.
    • 107
    Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
    • 235
    • PDF
    Pushing estrogen receptor around in breast cancer.
    • 26
    • PDF
    Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
    • 43
    • PDF
    Targeting the androgen receptor in prostate and breast cancer: several new agents in development.
    • 60
    • PDF
    Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy
    • 15
    • PDF
    Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts
    • 9
    Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
    • 246
    • PDF